Ghosh P C, Bachhawat B K
University of Delhi, India.
Targeted Diagn Ther. 1991;4:87-103.
We began our investigations about 15 years ago with the concept that it should be possible to deliver drugs or enzymes intracellularly into lysosomes for diseases associated with lysosomal enzymes (e.g., sphingolipidosis). The results have been very gratifying. It now has been possible to extend our in vitro studies on the kinetics of lectin-liposome interaction to the targeting of glycolipid liposomes to specific liver cell types in vivo by simply varying the sugar residue on the surface of liposome. Nevertheless, much remains to be done to ascertain the stability of the external enzyme and the expression of its activity after the delivery into the lysosomes.
大约15年前，我们开始了相关研究，其理念是对于与溶酶体酶相关的疾病（如鞘脂沉积症），应该能够将药物或酶细胞内递送至溶酶体中。结果非常令人满意。现在，通过简单改变脂质体表面的糖残基，已能够将我们关于凝集素 - 脂质体相互作用动力学的体外研究扩展至体内糖脂脂质体对特定肝细胞类型的靶向作用。然而，要确定外部酶在递送至溶酶体后的稳定性及其活性表达，仍有许多工作要做。
